 Patients with preexisting papilledema or with involvement of the central nervous system may be at higher risk.In postmarketing studies isolated cases of severe ventricular arrhythmias and renal failure have been seen.Injection site reaction like have also been observed (dermatitis, pain, and discoloration), but are usually mild.